Abstract
Growth factors and other trophic hormones play an important role in the specific treatment of intestinal failure, with teduglutide being the first approved medication specifically for use in patients with intestinal failure in conjunction with specialized nutritional support. This article focusses on the mode of action, the pivotal study data, treatment response prediction as well as new substances in phase clinical trials.
References
1.
McMellen
ME
, Wakeman
D
, Longshore
SW
, McDuffie
LA
, Warner
BW
. Growth factors: possible roles for clinical management of the short bowel syndrome
. Semin Pediatr Surg
. 2010
Feb
;19
(1
):35
–43
.
[PubMed]
1055-85862.
Buchman
AL
, Scolapio
J
, Fryer
J
. AGA technical review on short bowel syndrome and intestinal transplantation
. Gastroenterology
. 2003
Apr
;124
(4
):1111
–34
.
[PubMed]
0016-50853.
Scolapio
JS
. Short bowel syndrome: recent clinical outcomes with growth hormone
. Gastroenterology
. 2006
Feb
;130
(2
Suppl 1
):S122
–6
.
[PubMed]
0016-50854.
Steiger
E
. Guidelines for pharmacotherapy, nutritional management, and weaning parenteral nutrition in adult patients with short bowel syndrome: introduction
. J Clin Gastroenterol
. 2006
May-Jun
;40
Suppl 2
:S73
–4
.
[PubMed]
0192-07905.
Jeppesen
PB
, Pertkiewicz
M
, Messing
B
, Iyer
K
, Seidner
DL
, O’keefe
SJ
, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure
. Gastroenterology
. 2012
Dec
;143
(6
):1473
–1481.e3
.
[PubMed]
0016-50856.
Schwartz
LK
, O’Keefe
SJ
, Fujioka
K
, Gabe
SM
, Lamprecht
G
, Pape
UF
, et al. Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
. Clin Transl Gastroenterol
. 2016
Feb
;7
(2
):e142
.
[PubMed]
2155-384X7.
Cheeseman
CI
, Tsang
R
. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport
. Am J Physiol
. 1996
Sep
;271
(3 Pt 1
):G477
–82
.
[PubMed]
0002-95138.
Jeppesen
PB
, Sanguinetti
EL
, Buchman
A
, Howard
L
, Scolapio
JS
, Ziegler
TR
, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
. Gut
. 2005
Sep
;54
(9
):1224
–31
.
[PubMed]
0017-57499.
Ukleja
A
, To
C
, Alvarez
A
, Lara
LF
. Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series
. JPEN J Parenter Enteral Nutr
. 2018
May
;42
(4
):821
–5
.
[PubMed]
0148-607110.
Jeppesen
PB
, Gilroy
R
, Pertkiewicz
M
, Allard
JP
, Messing
B
, O’Keefe
SJ
. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
. Gut
. 2011
Jul
;60
(7
):902
–14
.
[PubMed]
0017-574911.
O’Keefe
SJ
, Jeppesen
PB
, Gilroy
R
, Pertkiewicz
M
, Allard
JP
, Messing
B
. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure
. Clin Gastroenterol Hepatol
. 2013
Jul
;11
(7
):815
–23.e1
.
[PubMed]
1542-356512.
Carter
BA
, Cohran
VC
, Cole
CR
, Corkins
MR
, Dimmitt
RA
, Duggan
C
, et al. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome
. J Pediatr
. 2017
Feb
;181
:102
–111.e5
.
[PubMed]
0022-347613.
Schoeler
M
, Klag
T
, Wendler
J
, Bernhard
S
, Adolph
M
, Kirschniak
A
, et al. GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting
. Therap Adv Gastroenterol
. 2018
Aug
;11
:1756284818793343
.
[PubMed]
1756-283X14.
Naimi
RM
, Hvistendahl
M
, Enevoldsen
LH
, Madsen
JL
, Fuglsang
S
, Poulsen
SS
, et al. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial
. Lancet Gastroenterol Hepatol
. 2019
May
;4
(5
):354
–63
.
[PubMed]
2468-1253© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.